Unexpected role for the human Cx37 C1019T polymorphism in tumour cell proliferation

Carcinogenesis

Volumn 31, Issue 11, 2010, Pages 1922-1931

  Morel, Sandrine ^a   Burnier, Laurent ^a   Roatti, Angela ^a   Chassot, Alexandra ^a   Roth, Isabelle ^a   Sutter, Esther ^a   Galan, Katia ^a   Pfenniger, Anna ^a   Chanson, Marc ^a   Kwak, Brenda R ^a  

^a UNIVERSITY OF GENEVA   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

2 (3 CHLORO 4 HYDROXYANILINO) 3 (2 NITROPHENYL)MALEIMIDE; CONNEXIN 37; CYSTEINE; GLYCOGEN SYNTHASE KINASE 3; LITHIUM CHLORIDE; NEUROBIOTIN; THREONINE; TRACER; UNCLASSIFIED DRUG;

ARTICLE; CARBOXY TERMINAL SEQUENCE; CELL COMMUNICATION; CELL PROLIFERATION; CELL STRAIN; CELL STRAIN SK HEP 1; CONTROLLED STUDY; DNA POLYMORPHISM; ENZYME INHIBITION; ENZYME PHOSPHORYLATION; GAP JUNCTION INTERCELLULAR COMMUNICATION; GENE VECTOR; GENETIC TRANSFECTION; HELA CELL; HUMAN; HUMAN CELL; IN VITRO STUDY; MICROINJECTION; PRIORITY JOURNAL; PROTEIN EXPRESSION; TUMOR CELL; TUMOR GROWTH;

BLOTTING, WESTERN; CELL COMMUNICATION; CELL CYCLE; CELL PROLIFERATION; CONNEXINS; FLUORESCENT ANTIBODY TECHNIQUE; GAP JUNCTIONS; GLYCOGEN SYNTHASE KINASE 3; HELA CELLS; HUMANS; NEOPLASMS; PHOSPHORYLATION; POLYMORPHISM, GENETIC; RECOMBINANT PROTEINS; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; RNA, SMALL INTERFERING;

EID: 78149237287     PISSN: 01433334     EISSN: 14602180     Source Type: Journal    
DOI: 10.1093/carcin/bgq170     Document Type: Article

References (52)

1. Goodenough, D.A. et al. (2003) Beyond the gap: functions of unpaired connexon channels. Nat. Rev. Mol. Cell Biol., 4, 285-294.
2. Saez, J.C. et al. (2003) Plasma membrane channels formed by connexins: their regulation and functions. Physiol. Rev., 83, 1359-1400.
3. Brisset, A.C. et al. (2009) Connexins in vascular physiology and pathology. Antioxid. Redox Signal., 11, 267-282.
4. White, T.W. (2003) Nonredundant gap junction functions. News Physiol. Sci., 18, 95-99.
5. Thomas, M.A. et al. (2002) Interaction of connexins with protein partners in the control of channel turnover and gating. Biol. Cell, 94, 445-456.
6. Mesnil, M. et al. (1995) Negative growth control of HeLa cells by connexin genes: connexin species specificity. Cancer Res., 55, 629-639.
7. Cronier, L. et al. (2009) Gap junctions and cancer: new functions for an old story. Antioxid. Redox Signal., 11, 323-338.
8. Defamie, N. et al. (2001) Disruption of gap junctional intercellular communication by lindane is associated with aberrant localization of connexin43 and zonula occludens-1 in 42GPA9 Sertoli cells. Carcinogenesis, 22, 1537-1542.
9. Govindarajan, R. et al. (2002) Impaired trafficking of connexins in androgen-independent human prostate cancer cell lines and its mitigation by alpha-catenin. J. Biol. Chem., 277, 50087-50097.
10. de Feijter, A.W. et al. (1996) Localization and function of the connexin 43 gap-junction protein in normal and various oncogene-expressing rat liver epithelial cells. Mol. Carcinog., 16, 203-212.
11. Eghbali, B. et al. (1991) Involvement of gap junctions in tumorigenesis: transfection of tumor cells with connexin 32 cDNA retards growth in vivo. Proc. Natl Acad. Sci. USA, 88, 10701-10705.
12. Mehta, P.P. et al. (1991) Incorporation of the gene for a cell-cell channel protein into transformed cells leads to normalization of growth. J. Membr. Biol., 124, 207-225.
13. Zhu, D. et al. (1991) Transfection of C6 glioma cells with connexin 43 cDNA: analysis of expression, intercellular coupling, and cell proliferation. Proc. Natl Acad. Sci. USA, 88, 1883-1887.
14. Naus, C.C. et al. (1992) In vivo growth of C6 glioma cells transfected with connexin43 cDNA. Cancer Res., 52, 4208-4213.
15. Rose, B. et al. (1993) Gap-junction protein gene suppresses tumorigenicity. Carcinogenesis, 14, 1073-1075.
16. Mesnil, M. et al. (2005) Defective gap junctional intercellular communication in the carcinogenic process. Biochim. Biophys. Acta, 1719, 125-145.
17. Mandelboim, O. et al. (1994) CTL induction by a tumour-associated antigen octapeptide derived from a murine lung carcinoma. Nature, 369, 67-71.
18. Berke, G. et al. (2003) Connexin 37 gene is not mutated in lung carcinomas 3LL and CMT. Cancer Lett., 195, 67-72.
19. Saito, T. et al. (1997) Connexin 37 mutations in rat hepatic angiosarcomas induced by vinyl chloride. Cancer Res., 57, 375-377.
20. Chanson, M. et al. (2007) Connexin37: a potential modifier gene of inflammatory disease. J. Mol. Med., 85, 787-795.
21. Morel, S. et al. (2009) Connexins participate in the initiation and progression of atherosclerosis. Semin. Immunopathol., 31, 49-61.
22. Wong, C.W. et al. (2006) Connexin37 protects against atherosclerosis by regulating monocyte adhesion. Nat. Med., 12, 950-954.
23. Derouette, J.P. et al. (2009) Functional differences between human Cx37 polymorphic hemichannels. J. Mol. Cell. Cardiol., 46, 499-507.
24. Saito, T. et al. (2000) Human hemangiosarcomas have a common polymorphism but no mutations in the connexin37 gene. Int. J. Cancer, 86, 67-70.
25. Jennings, R.C. et al. (1978) Haemangioendothelioma (Kupffer cell angiosarcoma), myelofibrosis, splenic atrophy, and myeloma paraproteinaemia after parenteral thorotrast administration. J. Clin. Pathol., 31, 1125-1132.
26. Pirastu, R. et al. (1990) Mortality from liver disease among Italian vinyl chloride monomer/polyvinyl chloride manufacturers. Am. J. Ind. Med., 17, 155-161.
27. Eldar-Finkelman, H. (2002) Glycogen synthase kinase 3: an emerging therapeutic target. Trends Mol. Med., 8, 126-132.
28. Jope, R.S. et al. (2007) Glycogen synthase kinase-3 (GSK3): inflammation, diseases, and therapeutics. Neurochem. Res., 32, 577-595.
29. Wilkins, J.A. et al. (1991) Beta 1 integrin-mediated lymphocyte adherence to extracellular matrix is enhanced by phorbol ester treatment. Eur. J. Immunol., 21, 517-522.
30. Blom, N. et al. (2004) Prediction of post-translational glycosylation and phosphorylation of proteins from the amino acid sequence. Proteomics, 4, 1633-1649.
31. Duffy, H.S. et al. (2002) pH-dependent intramolecular binding and structure involving Cx43 cytoplasmic domains. J. Biol. Chem., 277, 36706-36714.
32. Pfenniger, A. et al. (2010) The gap junction protein Cx37 interacts with eNOS in endothelial cells. Arterioscler. Thromb. Vasc. Biol., 30, 827-834.
33. Chanson, M. et al. (1999) Defective regulation of gap junctional coupling in cystic fibrosis pancreatic duct cells. J. Clin. Invest., 103, 1677-1684.
34. Larson, D.M. et al. (2000) Functional expression and biochemical characterization of an epitope-tagged connexin37. Mol. Cell Biol. Res. Commun., 3, 115-121.
35. Fiol, C.J. et al. (1987) Formation of protein kinase recognition sites by covalent modification of the substrate. Molecular mechanism for the synergistic action of casein kinase II and glycogen synthase kinase 3. J. Biol. Chem., 262, 14042-14048.
36. Doble, B.W. et al. (2003) GSK-3: tricks of the trade for a multi-tasking kinase. J. Cell Sci., 116, 1175-1186.
37. Cohen, P. et al. (2004) GSK3 inhibitors: development and therapeutic potential. Nat. Rev. Drug Discov., 3, 479-487.
38. Frame, S. et al. (2001) GSK3 takes centre stage more than 20 years after its discovery. Biochem. J., 359, 1-16.
39. Meijer, L. et al. (2004) Pharmacological inhibitors of glycogen synthase kinase 3. Trends Pharmacol. Sci., 25, 471-480.
40. Coghlan, M.P. et al. (2000) Selective small molecule inhibitors of glycogen synthase kinase-3 modulate glycogen metabolism and gene transcription. Chem. Biol., 7, 793-803.
41. Burt, J.M. et al. (2008) Connexin 37 profoundly slows cell cycle progression in rat insulinoma cells. Am. J. Physiol. Cell Physiol., 295, C1103-C12.
42. Krutovskikh, V. et al. (1996) Human connexin 37 is polymorphic but not mutated in tumours. Carcinogenesis, 17, 1761-1763.
43. Takens-Kwak, B.R. et al. (1992) Cardiac gap junctions: three distinct single channel conductances and their modulation by phosphorylating treatments. Pflugers Arch., 422, 198-200.
44. Dang, X. et al. (2003) The carboxy-tail of connexin-43 localizes to the nucleus and inhibits cell growth. Mol. Cell. Biochem., 242, 35-38.
45. Doble, B.W. et al. (2004) Phosphorylation of serine 262 in the gap junction protein connexin-43 regulates DNA synthesis in cell-cell contact forming cardiomyocytes. J. Cell Sci., 117, 507-514.
46. Embi, N. et al. (1980) Glycogen synthase kinase-3 from rabbit skeletal muscle. Separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase. Eur. J. Biochem., 107, 519-527.
47. Rayasam, G.V. et al. (2009) Glycogen synthase kinase 3: more than a namesake. Br. J. Pharmacol., 156, 885-898.
48. Thomas, G.M. et al. (1999) AGSK3-binding peptide from FRAT1 selectively inhibits the GSK3-catalysed phosphorylation of axin and beta-catenin. FEBS Lett., 458, 247-251.
49. Du, W.J. et al. (2008) Lithium chloride regulates connexin43 in skeletal myoblasts in vitro: possible involvement in Wnt/beta-catenin signaling. Cell Commun. Adhes., 15, 261-271.
50. Du, W.J. et al. (2009) Lithium chloride preconditioning optimizes skeletal myoblast functions for cellular cardiomyoplasty in vitro via glycogen synthase kinase-3beta/beta-catenin signaling. Cells Tissues Organs, 190, 11-19.
51. Goldberg, G.S. et al. (2002) Gap junctions between cells expressing connexin 43 or 32 show inverse permselectivity to adenosine and ATP. J. Biol. Chem., 277, 36725-36730.
52. Upham, B.L. et al. (2003) Reduced gap junctional intercellular communication and altered biological effects in mouse osteoblast and rat liver oval cell lines transfected with dominant-negative connexin 43. Mol. Carcinog., 37, 192-201.